Prevention of age-related spatial memory deficits in a transgenic mouse model of Alzheimer's disease by chronic Ginkgo biloba treatment

Experimental Neurology

Volumn 184, Issue 1, 2003, Pages 510-520

  Stackman, Robert W ^a   Eckenstein, Felix ^a,d   Frei, Balz ^b   Kulhanek, Doris ^a   Nowlin, Jessica ^a   Quinn, Joseph F ^a,c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON STATE UNIVERSITY   (United States)

^c PORTLAND VA MEDICAL CENTER   (United States)

^d UNIVERSITY OF VERMONT   (United States)

Author keywords

Alzheimer; Amyloid; Antioxidant; Hippocampus; Oxidative stress; Spatial learning; Spatial memory; Tg2576

Indexed keywords

ANTIOXIDANT; CARBONYL DERIVATIVE; GINKGO BILOBA EXTRACT; TAP WATER;

AGE; ALZHEIMER DISEASE; AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; BRAIN LEVEL; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; DRUG MECHANISM; DRUG SCREENING; FEMALE; GINKGO BILOBA; HIPPOCAMPUS; LEARNING; MAZE TEST; MEMORY CONSOLIDATION; MOUSE; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; SPATIAL MEMORY; SWIMMING; TIME; TRANSGENIC MOUSE; WILD TYPE;

EID: 0344826082     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-4886(03)00399-6     Document Type: Article

References (81)

1. Abbas N., Bednar I., Mix E., Marie S., Paterson D., Ljungberg A., Morris C., Winblad B., Nordberg A., Zhu J. Up-regulation of the inflammatory cytokines IFN-gamma and IL-12 and down-regulation of IL-4 in cerebral cortex regions of APP(SWE) transgenic mice. J. Neuroimmunol. 126:2002;50-57.
2. Aksenov M., Aksenova M., Butterfield D.A., Markesbery W.R. Oxidative modification of creatine kinase BB in Alzheimer's disease brain. J. Neurochem. 74:2000;2520-2527.
3. Barkats M., Venault P., Christen Y., Cohen-Salmon C. Effect of long-term treatment with EGb 761 on age-dependent structural changes in the hippocampi of three inbred mouse strains. Life Sci. 56:1995;213-222.
4. Bastianetto S., Quirion R. Natural extracts as possible protective agents of brain aging. Neurobiol. Aging. 23:2002;891-897.
5. Bastianetto S., Ramassamy C., Dore S., Christen Y., Poirier J., Quirion R. The Ginkgo biloba extract (EGb 761) protects hippocampal neurons against cell death induced by beta-amyloid. Eur. J. Neurosci. 12:2000;1882-1890.
6. Behl C., Davis J., Cole G.M., Schubert D. Vitamin E protects nerve cells from amyloid beta protein toxicity. Biochem. Biophys. Res. Commun. 186:1992;944-950.
7. Behl C., Davis J.B., Lesley R., Schubert D. Hydrogen peroxide mediates amyloid beta protein toxicity. Cell. 77:1994;817-827.
8. Chandrasekaran K., Mehrabian Z., Spinnewyn B., Chinopoulos C., Drieu K., Fiskum G. Bilobalide, a component of the Ginkgo biloba extract (EGb 761), protects against neuronal death in global brain ischemia and in glutamate-induced excitotoxicity. Cell. Mol. Biol. (Noisy-le-grand). 48:2002;663-669.
9. Chandrasekaran K., Mehrabian Z., Spinnewyn B., Drieu K., Fiskum G. Neuroprotective effects of bilobalide, a component of the Ginkgo biloba extract (EGb 761), in gerbil global brain ischemia. Brain Res. 922:2001;282-292.
10. Chapman P.F., White G.L., Jones M.W., Cooper-Blacketer D., Marshall V.J., Irizarry M., Younkin L., Good M.A., Bliss T.V., Hyman B.T., Younkin S.G., Hsiao K.K. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat. Neurosci. 2:1999;271-276.
11. Christen Y., Maixent J.M. What is Ginkgo biloba extract EGb 761? An overview - from molecular biology to clinical medicine. Cell. Mol. Biol. (Noisy-le-grand). 48:2002;601-611.
12. Cohen-Salmon C., Venault P., Martin B., Raffalli-Sebille M.J., Barkats M., Clostre F., Pardon M.C., Christen Y., Chapouthier G. Effects of Ginkgo biloba extract (EGb 761) on learning and possible actions on aging. J. Physiol. Paris. 91:1997;291-300.
13. Coyle J.T., Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science. 262:1993;689-695.
14. Crawford F., Suo Z., Fang C., Mullan M. Characteristics of the in vitro vasoactivity of beta-amyloid peptides. Exp. Neurol. 150:1998;159-168.
15. Diamond B.J., Shiflett S.C., Feiwel N., Matheis R.J., Noskin O., Richards J.A., Schoenberger N.E. Ginkgo biloba extract mechanisms and clinical indications. Arch. Phys. Med. Rehabil. 81:2000;668-678.
16. Dineley K.T., Westerman M., Bui D., Bell K., Ashe K.H., Sweatt J.D. Beta-amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine receptors In vitro and in vivo mechanisms related to Alzheimer's disease. J. Neurosci. 21:2001;4125-4133.
17. Doody R.S., Stevens J.C., Beck C., Dubinsky R.M., Kaye J.A., Gwyther L., Mohs R.C., Thal L.J., Whitehouse P.J., DeKosky S.T., Cummings J.L. Practice parameter management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 56:2001;1154-1166.
18. Floyd R.A. Antioxidants, oxidative stress, and degenerative neurological disorders. Proc. Soc. Exp. Biol. Med. 222:1999;236-245.
19. Freo U., Pizzolato G., Dam M., Ori C., Battistin L. A short review of cognitive and functional neuroimaging studies of cholinergic drugs implications for therapeutic potentials. J. Neural Transm. 109:2002;857-870.
20. Gallagher M., Burwell R., Burchinal M. Severity of spatial learning impairment in aging development of a learning index for performance in the Morris water maze. Behav. Neurosci. 107:1993;618-626.
21. Gau J.T., Steinhilb M.L., Kao T.C., D'Amato C.J., Gaut J.R., Frey K.A., Turner R.S. Stable beta-secretase activity and presynaptic cholinergic markers during progressive central nervous system amyloidogenesis in Tg2576 mice. Am. J. Pathol. 160:2002;731-738.
22. Hsiao K. Transgenic mice expressing Alzheimer amyloid precursor proteins. Exp. Gerontol. 33:1998;883-889.
23. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science. 274:1996;99-102.
24. Iliff L.D., Auer L.M. The effect of intravenous infusion of Tebonin (Ginkgo biloba) on pial arteries in cats. J. Neurosurg. Sci. 27:1983;227-231.
25. Irizarry M.C., McNamara M., Fedorchak K., Hsiao K., Hyman B.T. APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. J. Neuropathol. Exp. Neurol. 56:1997;965-973.
26. Janus C., Westaway D. Transgenic mouse models of Alzheimer's disease. Physiol. Behav. 73:2001;873-886.
27. Kanowski S., Herrmann W.M., Stephan K., Wierich W., Horr R. Proof of efficacy of the ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. Pharmacopsychiatry. 29:1996;47-56.
28. Kawarabayashi T., Younkin L.H., Saido T.C., Shoji M., Ashe K.H., Younkin S.G. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J. Neurosci. 21:2001;372-381.
29. Kennedy D.O., Scholey A.B., Wesnes K.A. The dose-dependent cognitive effects of acute administration of Ginkgo biloba to healthy young volunteers. Psychopharmacology. 151:2000;416-423.
30. Kennedy D.O., Scholey A.B., Wesnes K.A. Differential, dose dependent changes in cognitive performance following acute administration of a Ginkgo biloba/Panax ginseng combination to healthy young volunteers. Nutr. Neurosci. 4:2001;399-412.
31. King D.L., Arendash G.W. Behavioral characterization of the Tg2576 transgenic model of Alzheimer's disease through 19 months. Physiol. Behav. 75:2002;627-642.
32. Klein J., Chatterjee S.S., Loffelholz K. Phospholipid breakdown and choline release under hypoxic conditions inhibition by bilobalide, a constituent of Ginkgo biloba. Brain Res. 755:1997;347-350.
33. Kwak W.J., Han C.K., Son K.H., Chang H.W., Kang S.S., Park B.K., Kim H.P. Effects of Ginkgetin from Ginkgo biloba leaves on cyclooxygenases and in vivo skin inflammation. Planta Med. 68:2002;316-321.
34. Le Bars P.L., Katz M.M., Berman N., Itil T.M., Freedman A.M., Schatzberg A.F. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. JAMA. 278:1997;1327-1332.
35. Le R., Cruz L., Urbanc B., Knowles R.B., Hsiao-Ashe K., Duff K., Irizarry M.C., Stanley H.E., Hyman B.T. Plaque-induced abnormalities in neurite geometry in transgenic models of Alzheimer disease implications for neural system disruption. J. Neuropathol. Exp. Neurol. 60:2001;753-758.
36. Lim G.P., Chu T., Yang F., Beech W., Frautschy S.A., Cole G.M. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J. Neurosci. 21:2001;8370-8377.
37. Lim G.P., Yang F., Chu T., Gahtan E., Ubeda O., Beech W., Overmier J.B., Hsiao-Ashe K., Frautschy S.A., Cole G.M. Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiol. Aging. 22:2001;983-991.
38. Lipp H.P., Wolfer D.P. Genetically modified mice and cognition. Curr. Opin. Neurobiol. 8:1998;272-280.
39. Luo Y., Smith J.V., Paramasivam V., Burdick A., Curry K.J., Buford J.P., Khan I., Netzer W.J., Xu H., Butko P. Inhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761. Proc. Natl. Acad. Sci. USA. 99:2002;12197-12202.
40. Maclennan K.M., Darlington C.L., Smith P.F. The CNS effects of Ginkgo biloba extracts and ginkgolide B. Prog. Neurobiol. 67:2002;235-257.
41. Maitra I., Marcocci L., Droy-Lefaix M.T., Packer L. Peroxyl radical scavenging activity of Ginkgo biloba extract EGb 761. Biochem. Pharmacol. 49:1995;1649-1655.
42. Manelli A.M., Puttfarcken P.S. beta-Amyloid-induced toxicity in rat hippocampal cells in vitro evidence for the involvement of free radicals. Brain Res. Bull. 38:1995;569-576.
43. Markesbery W.R., Carney J.M. Oxidative alterations in Alzheimer's disease. Brain Pathol. 9:1999;133-146.
44. Mattson M.P., Chan S.L. Dysregulation of cellular calcium homeostasis in Alzheimer's disease bad genes and bad habits. J. Mol. Neurosci. 17:2001;205-224.
45. Maurer K., Ihl R., Dierks T., Frolich L. Clinical efficacy of Ginkgo biloba special extract EGb 761 in dementia of the Alzheimer type. J. Psychiatr. Res. 31:1997;645-655.
46. Montine T.J., Markesbery W.R., Zackert W., Sanchez S.C., Roberts L.J. 2nd, Morrow J.D. The magnitude of brain lipid peroxidation correlates with the extent of degeneration but not with density of neuritic plaques or neurofibrillary tangles or with APOE genotype in Alzheimer's disease patients. Am. J. Pathol. 155:1999;863-868.
47. Morris R.G.M. Developments of a water-maze procedure for studying spatial learning in the rat. J. Neurosci. Methods. 11:1984;47-60.
48. Morris R.G.M., Garrud P., Rawlins J.N.P., O'Keefe J. Place navigation impaired in rats with hippocampal lesions. Nature. 297:1982;681-683.
49. Nathan P. Can the cognitive enhancing effects of ginkgo biloba be explained by its pharmacology? Med. Hypotheses. 55:2000;491-493.
50. Nunomura A., Perry G., Aliev G., Hirai K., Takeda A., Balraj E.K., Jones P.K., Ghanbari H., Wataya T., Shimohama S., Chiba S., Atwood C.S., Petersen R.B., Smith M.A. Oxidative damage is the earliest event in Alzheimer disease. J. Neuropathol. Exp. Neurol. 60:2001;759-767.
51. Oken B.S., Storzbach D.M., Kaye J.A. The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. Arch. Neurol. 55:1998;1409-1415.
52. Oyama Y., Fuchs P.A., Katayama N., Noda K. Myricetin and quercetin, the flavonoid constituents of Ginkgo biloba extract, greatly reduce oxidative metabolism in both resting and Ca(2+)-loaded brain neurons. Brain Res. 635:1994;125-129.
53. Pappolla M.A., Chyan Y.J., Omar R.A., Hsiao K., Perry G., Smith M.A., Bozner P. Evidence of oxidative stress and in vivo neurotoxicity of beta-amyloid in a transgenic mouse model of Alzheimer's disease a chronic oxidative paradigm for testing antioxidant therapies in vivo. Am. J. Pathol. 152:1998;871-877.
54. Paris D., Town T., Parker T.A., Humphrey J., Mullan M. Isoform-specific vasoconstriction induced by apolipoprotein E and modulation of this effect by Alzheimer's beta-amyloid peptide. Neurosci. Lett. 256:1998;73-76.
55. Pratico D., Uryu K., Leight S., Trojanoswki J.Q., Lee V.M. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J. Neurosci. 21:2001;4183-4187.
56. Pratico D., Uryu K., Sung S., Tang S., Trojanowski J.Q., Lee V.M. Aluminum modulates brain amyloidosis through oxidative stress in APP transgenic mice. FASEB J. 16:2002;1138-1140.
57. Pratico, D., Lee, V.M., Trojanowski, J.Q., Rokach, J., Fitzgerald, G.A., 1998. Increased F2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo. FASEB J. 12, 1777-1783.
58. Prehn J.H., Krieglstein J. Platelet-activating factor antagonists reduce excitotoxic damage in cultured neurons from embryonic chick telencephalon and protect the rat hippocampus and neocortex from ischemic injury in vivo. J. Neurosci. Res. 34:1993;179-188.
59. Price D.L., Tanzi R.E., Borchelt D.R., Sisodia S.S. Alzheimer's disease genetic studies and transgenic models. Annu. Rev. Genet. 32:1998;461-493.
60. Puttfarcken P.S., Manelli A.M., Neilly J., Frail D.E. Inhibition of age-induced beta-amyloid neurotoxicity in rat hippocampal cells. Exp. Neurol. 138:1996;73-81.
61. Quinn J., Davis F., Woodward W.R., Eckenstein F. Beta-amyloid plaques induce neuritic dystrophy of nitric oxide-producing neurons in a transgenic mouse model of Alzheimer's disease. Exp. Neurol. 168:2001;203-212.
62. Reisberg B., Doody R., Stoffler A., Schmitt F., Ferris S., Mobius H.J. Memantine in moderate-to-severe Alzheimer's disease. N. Engl. J. Med. 348:2003;1333-1341.
63. Sano M., Ernesto C., Thomas R.G., Klauber M.R., Schafer K., Grundman M., Woodbury P., Growdon J., Cotman C.W., Pfeiffer E., Schneider L.S., Thal L.J. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N. Engl. J. Med. 336:1997;1216-1222.
64. Sastre, J., Millan, A., Garcia de la Asuncion, J., Pla, R., Juan, G., Pallardo, O'Connor, E., Martin, J.A., Droy-Lefaix, M.T., Vina, J., 1998. A Ginkgo biloba extract (EGb 761) prevents mitochondrial aging by protecting against oxidative stress. Free Radic. Biol. Med. 24, 298-304.
65. Silva A.J., Giese K.P., Federov N.B., Frankland P.W., Kogan J.H. Molecular, cellular, and neuroanatomical substrates of place learning. Neurobiol. Learn. Memory. 70:1998;44-61.
66. Smith C.D., Carney J.M., Starke-Reed P.E., Oliver C.N., Stadtman E.R., Floyd R.A., Markesbery W.R. Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. Proc. Natl. Acad. Sci. USA. 88:1991;10540-10543.
67. Smith M.A., Hirai K., Hsiao K., Pappolla M.A., Harris P.L., Siedlak S.L., Tabaton M., Perry G. Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress. J. Neurochem. 70:1998;2212-2215.
68. Solomon P.R., Adams F., Silver A., Zimmer J., DeVeaux R. Ginkgo for memory enhancement a randomized controlled trial. JAMA. 288:2002;835-840.
69. + channels modulate synaptic plasticity and memory encoding. J. Neurosci. 22:2002;10163-10171.
70. Tang F., Nag S., Shiu S.Y., Pang S.F. The effects of melatonin and Ginkgo biloba extract on memory loss and choline acetyltransferase activities in the brain of rats infused intracerebroventricularly with beta-amyloid 1-40. Life Sci. 71:2002;2625-2631.
71. Tehranian R., Hasanvan H., Iverfeldt K., Post C., Schultzberg M. Early induction of interleukin-6 mRNA in the hippocampus and cortex of APPsw transgenic mice Tg2576. Neurosci Lett. 301:2001;54-58.
72. Thomas T., Thomas G., McLendon C., Sutton T., Mullan M. Beta-amyloid-mediated vasoactivity and vascular endothelial damage. Nature. 380:1996;168-171.
73. Weichel O., Hilgert M., Chatterjee S.S., Lehr M., Klein J. Bilobalide, a constituent of Ginkgo biloba, inhibits NMDA-induced phospholipase A2 activation and phospholipid breakdown in rat hippocampus. Naunyn Schmiedebergs Arch. Pharmacol. 360:1999;609-615.
74. Wesnes K.A., Ward T., McGinty A., Petrini O. The memory enhancing effects of a Ginkgo biloba/Panax ginseng combination in healthy middle-aged volunteers. Psychopharmacology. 152:2000;353-361.
75. Westerman M.A., Cooper-Blacketer D., Mariash A., Kotilinek L., Kawarabayashi T., Younkin L.H., Carlson G.A., Younkin S.G., Ashe K.H. The relationship between Aβ and memory in the Tg2576 mouse model of Alzheimer's disease. J. Neurosci. 22:2002;1858-1867.
76. Winkler J., Thal L.J., Gage F.H., Fisher L.J. Cholinergic strategies for Alzheimer's disease. J. Mol. Med. 76:1998;555-567.
77. Winter E. Effects of an extract of Ginkgo biloba on learning and memory in mice. Pharmacol. Biochem. Behav. 38:1991;109-114.
78. Wirth S., Stemmelin J., Will B., Christen Y., Di Scala G. Facilitative effects of EGb 761 on olfactory recognition in young and aged rats. Pharmacol. Biochem. Behav. 65:2000;321-326.
79. Wolfer D.P., Lipp H.P. Dissecting the behaviour of transgenic mice is it the mutation, the genetic background, or the environment? Exp. Physiol. 85:2000;627-634.
80. Yamada K., Tanaka T., Han D., Senzaki K., Kameyama T., Nabeshima T. Protective effects of idebenone and alpha-tocopherol on beta-amyloid-(1-42)- induced learning and memory deficits in rats implication of oxidative stress in beta-amyloid-induced neurotoxicity in vivo. Eur. J. Neurosci. 11:1999;83-90.
81. Yao Z., Drieu K., Papadopoulos V. The Ginkgo biloba extract EGb 761 rescues the PC12 neuronal cells from beta-amyloid-induced cell death by inhibiting the formation of beta-amyloid-derived diffusible neurotoxic ligands. Brain Res. 889:2001;181-190.